26.03.2020 07:14

Press Release: Novartis and Life Sciences Companies Commit Expertise and Assets to the Fight Against COVID-19 Pandemic alongside Bill & Melinda Gates Foundation


-- Collaboration to address product development and scale up challenges

posed by current pandemic

Basel, March 26, 2020 -- Today, Novartis and a consortium of life

sciences companies announced an important collaboration to accelerate

the development, manufacture and delivery of vaccines, diagnostics, and

treatments for COVID-19 in response to the pandemic. The industry brings

a range of assets, resources, and expertise needed to identify effective

and scalable solutions to the pandemic that is affecting billions

worldwide. Effects on health systems, economies, and livelihoods are

significant, and effective response requires an unprecedented

collaboration across government, academia, private sector, and


As co-chair of a consortium of life science companies headquartered

across three continents, Vas Narasimhan, CEO of Novartis, said, "We feel

a deep shared responsibility to see if there are specific areas where

collaboration across the life sciences industry and the Bill & Melinda

Gates Foundation can accelerate solutions to this pandemic. In addition

to the individual contributions companies are already making, collective

action is critical to ensure any promising studies into vaccines, drugs,

and diagnostics are quickly scaled to people around the world who are

affected by this pandemic."

Trials of existing drugs, diagnostic tests, compounds, and

investigational vaccines have begun around the world to identify

interventions to slow or end the pandemic. Products that demonstrate

efficacy will require clinical study, scale up of manufacturing, and

distribution if proven effective. These are areas that the life sciences

industry has extensive experience in managing for products that reach

billions of people every day.

Mark Suzman, chief executive officer of the Bill & Melinda Gates

Foundation said, "We know that the private sector is where the technical

skills from discovery to clinical trials to commercialization know-how

sits. We look to harness that knowledge and experience, combine it where

possible, to connect with national regulators and the World Health

Organization to see if we can help flatten the curve of this pandemic

and make sure the results reach everyone around the world, particularly

those at highest risk and the poorest."

Following a conference call with Gates Foundation leadership earlier

this month, companies are working to identify concrete actions that will

accelerate treatments, vaccines, and diagnostics to the field. As a

first step, 15 companies have agreed to share their proprietary

libraries of molecular compounds that already have some degree of safety

and activity data -- with the COVID-19 Therapeutics Accelerator launched

by the Gates Foundation, Wellcome, and Mastercard two weeks ago to

quickly screen them for potential against COVID-19. Successful hits

would move rapidly into in vivo trials in as little as two months.

"This is an encouraging start in a critical area because if any of these

compounds are shown to be effective against COVID-19 it dramatically

accelerates the path to product approval and scale up," said Suzman.

"While each of the partners will also be pursuing other efforts in

partnership with national governments and other partners, it is a great

example of why we are optimistic that this unprecedented collaboration

will provide a platform for a fundamentally different kind of

partnership to help address this global health emergency."

Companies participating in the collaboration include:

BD, Boehringer Ingelheim, bioMerieux, Eisai, Eli Lilly, Gilead, GSK, J&J,

Merck (MSD), Merck (Merck KGaA), Novartis, Pfizer, Sanofi.


This press release contains forward-looking statements within the

meaning of the United States Private Securities Litigation Reform Act of

1995. Forward-looking statements can generally be identified by words

such as "potential," "can," "will," "would," "look," "commit,"

"investigational," "accelerate," "launch," "encouraging," or similar

terms, or by express or implied discussions regarding potential

marketing approvals, new indications or labeling for the investigational

or approved products described in this press release, or regarding the

collaboration to accelerate the development, manufacture and delivery of

vaccines, diagnostics and treatments for COVID-19. You should not place

undue reliance on these statements. Such forward-looking statements are

based on ouSHYr current beliefs and expectations regarding future events,

and are subject to significant known and unknown risks and

uncertainties. Should one or more of these risks or uncertainties

materialize, or should underlying assumptions prove incorrect, actual

results may vary materially from those set forth in the forward-looking

statements. There can be no guarantee that the investigational or

approved products described in this press release will be submitted or

approved for sale or for any additional indications or labeling in any

market, or at any particular time. Nor can there be any guarantee that

the activities and efforts described in this release will be achieved or

succeed, in the expected time frame, or at all. In particular, our

expectations regarding such products and efforts could be affected by,

among other things, the uncertainties inherent in research and

development, including clinical trial results and additional analysis of

existing clinical data; regulatory actions or delays or government

regulation generally; global trends toward health care cost containment,

including government, payor and general public pricing and reimbursement

pressures and requirements for increased pricing transparency; our

ability to obtain or maintain proprietary intellectual property

protection; the particular prescribing preferences of physicians and

patients; general political, economic and business conditions, including

the effects of and efforts to mitigate pandemic diseases such as

COVID-19; safety, quality, data integrity or manufacturing issues;

potential or actual data security and data privacy breaches, or

disruptions of our information technology systems, and other risks and

factors referred to in Novartis AG's current Form 20-F on file with the

US Securities and Exchange Commission. Novartis is providing the

information in this press release as of this date and does not undertake

any obligation to update any forward-looking statements contained in

this press release as a result of new information, future events or


About Novartis

Novartis is reimagining medicine to improve and extend people's lives.

As a leading global medicines company, we use innovative science and

digital technologies to create transformative treatments in areas of

great medical need. In our quest to find new medicines, we consistently

rank among the world's top companies investing in research and

development. Novartis products reach nearly 800 million people globally

and we are finding innovative ways to expand access to our latest

treatments. About 109,000 people of more than 145 nationalities work at

Novartis around the world. Find out more at

Novartis is on Twitter. Sign up to follow @Novartis at

For Novartis multimedia content, please visit

For questions about the site or required registration, please contact

About the Bill & Melinda Gates Foundation

Guided by the belief that every life has equal value, the Bill & Melinda

Gates Foundation works to help all people lead healthy, productive

lives. In developing countries, it focuses on improving people's health

and giving them the chance to lift themselves out of hunger and extreme

poverty. In the United States, it seeks to ensure that all

people--especially those with the fewest resources--have access to the

opportunities they need to succeed in school and life. Based in Seattle,

Washington, the foundation is led by CEO Mark Suzman and Co-chair

William H. Gates Sr., under the direction of Bill and Melinda Gates and

Warren Buffett.

# # #

Novartis Media Relations


Sreejit Mohan

Novartis Global External Communications

+41 79 747 91 57

Bill and Melinda Gates Foundation Media Contact:


Eric Althoff

Novartis US External Communications

+1 646 438 4335

Novartis Investor Relations

Central investor relations line: +41 61 324 7944


Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052

Pierre-Michel Bringer +41 61 324 1065

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188 Cory Twining +1 862 778 3258

(END) Dow Jones Newswires

March 26, 2020 02:15 ET (06:15 GMT)

Nachrichten zu Novartis AG

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Novartis AG

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
02.04.2020Novartis Conviction BuyGoldman Sachs Group Inc.
01.04.2020Novartis buyJefferies & Company Inc.
31.03.2020Novartis buyOddo BHF
24.03.2020Novartis UnderweightJP Morgan Chase & Co.
20.03.2020Novartis HoldDeutsche Bank AG
02.04.2020Novartis Conviction BuyGoldman Sachs Group Inc.
01.04.2020Novartis buyJefferies & Company Inc.
31.03.2020Novartis buyOddo BHF
25.02.2020Novartis buyJefferies & Company Inc.
30.01.2020Novartis Conviction Buy ListGoldman Sachs Group Inc.
20.03.2020Novartis HoldDeutsche Bank AG
11.03.2020Novartis Equal-WeightMorgan Stanley
26.02.2020Novartis HoldDeutsche Bank AG
25.02.2020Novartis NeutralUBS AG
31.01.2020Novartis HoldDeutsche Bank AG
24.03.2020Novartis UnderweightJP Morgan Chase & Co.
17.03.2020Novartis UnderweightBarclays Capital
25.02.2020Novartis UnderweightBarclays Capital
29.01.2020Novartis UnderweightJP Morgan Chase & Co.
27.01.2020Novartis UnderweightJP Morgan Chase & Co.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novartis AG nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX geht tiefer ins Wochenende -- US-Börsen schließen im Minus -- US-Arbeitsmarkt büßt massiv Stellen ein -- adidas braucht frisches Geld -- Tesla, PUMA, TRATON, Shop Apotheke, BNP im Fokus

DIC Asset senkt wegen Corona-Krise Gewinnprognose. Nordex profitiert von hoher Nachfrage in Europa. Bundesregierung in Gesprächen mit Lufthansa über Staatsbeteiligung. RTL zieht Ausblick und Dividendenvorschlag zurück. H&M: Q1-Zahlen besser als erwartet. Ryanair hält Gewinn noch im Prognoserahmen.

Die 5 beliebtesten Top-Rankings

Rohstoffe: Die Gewinner und Verlierer im März 2020
Welcher Rohstoff macht das Rennen?
DAX 30: Die Gewinner und Verlierer im März 2020
Welche Aktie macht das Rennen?
TecDAX: Die Gewinner und Verlierer in Q1 2020
Welche Aktie macht das Rennen?
Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
DAX: Die größten Verluste an nur einem Tag
An diesem Tagen verbuchte der DAX das höchste Minus
mehr Top Rankings


Corona-Crash und Chaostage an den Börsen. Wie handeln Sie in unsicheren Zeiten?

Online Brokerage über Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von!


Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Euro US-Dollar
Deutsche Bank AG514000
Scout24 AGA12DM8
Microsoft Corp.870747
Wirecard AG747206
Apple Inc.865985
Daimler AG710000
Lufthansa AG823212
Alphabet C (ex Google)A14Y6H
MasterCard Inc.A0F602
Shell (Royal Dutch Shell) (A)A0D94M
Airbus SE (ex EADS)938914